{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000043","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.650354+00:00","generated_at":"2026-05-15T00:58:19.899556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch","bullets":["Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.","Gross margin improved to 78% (from 75%) on lower array costs.","Optune Pax FDA approved for locally advanced pancreatic cancer; 169 prescriptions, 83 active patients as of March 31, 2026.","FY2026 revenue guidance raised to $690M-$710M (from $675M-$705M); Adj. EBITDA guidance narrowed to -$15M-$0M.","PANOVA-4 Phase 2 met primary endpoint with 74% disease control rate vs 48% historical control."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000043","json":"https://secwatch.observer/filing/0001645113-26-000043.json","markdown":"https://secwatch.observer/filing/0001645113-26-000043.md","text":"https://secwatch.observer/filing/0001645113-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/nvcr-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:58:19.899556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bbacc177fa8268e272778da5ab02775ba75c3c0","claim":"NovoCure Ltd reported first quarter ended March 31, 2026 results: revenue Total net revenues for the quarter were $174.1 million, net income Net loss for the quarter was $71.1 million, EPS loss per share of $0.62.","evidence_excerpt":"Novocure Reports First Quarter 2026 Financial Results Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio ® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 BAAR, Switzerland – April 30, 2026 - Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"Total net revenues for the quarter were $174.1 million"},{"label":"Net income","value":"Net loss for the quarter was $71.1 million"},{"label":"EPS","value":"loss per share of $0.62"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8a07118711ce4b4964d928278d6928c0d040cf2a","claim":"NovoCure Ltd reported full year 2026 results: revenue Total net revenue: $690 million - $710 million (previous: $675 million - $705 million). Guidance raised.","evidence_excerpt":"Novocure’s updated guidance for the full year 2026, as of April 30, 2026, is summarized below: • Total net revenue: $690 million - $710 million (previous: $675 million - $705 million) • Adjusted EBITDA*: $(15) million - $0 million (previous: $(20) million - $0 million)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2026"},{"label":"Revenue","value":"Total net revenue: $690 million - $710 million (previous: $675 million - $705 million)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}